Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TheraCea Pharma is developing next-generation radiolabeling technologies centered on Fluorine‑18 for PET imaging. Their approach enables faster, more accessible preparation of radiotracers without advanced on-site expertise. The company’s products are designed to improve the accuracy of cancer and neurological disorder diagnosis and facilitate personalized therapy selection. They have received multiple SBIR Phase I awards but do not yet have late-stage clinical results publicly available.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TheraCea Pharma.